Adhera Therapeutics, Inc.
ATRXOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$722
P/E Ratio—
52W High$0.01
52W Low$0.0001
Adhera Therapeutics, Inc. (ATRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ATRX · earnings · updated Jun 8, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 20, 2023EPS Actual
-$0.83
Revenue
—
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 20, 2023
After Market Close
ATRX reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q4 FY2023 | Nov 20, 2023 | — | -$0.83 | — | — | — | — |
| — Q3 FY2023 | Aug 21, 2023 | — | -$0.01 | — | — | — | — |
| — Q2 FY2023 | May 22, 2023 | — | -$0.29 | — | — | — | — |
| — Q1 FY2023 | Mar 31, 2023 | — | -$0.02 | — | — | — | — |
| — Q4 FY2022 | Dec 31, 2022 | — | $0.70 | — | — | — | — |
| — Q4 FY2022 | Nov 14, 2022 | — | -$0.57 | — | — | — | — |
| — Q3 FY2022 | Aug 15, 2022 | — | -$0.20 | — | — | — | — |
| — Q2 FY2022 | Apr 15, 2022 | — | -$2.20 | — | — | — | — |
Q4 FY2023
Nov 20, 2023
EPS Actual
-$0.83
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Aug 21, 2023
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2023
May 22, 2023
EPS Actual
-$0.29
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2023
Mar 31, 2023
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2022
Dec 31, 2022
EPS Actual
$0.70
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2022
Nov 14, 2022
EPS Actual
-$0.57
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2022
Aug 15, 2022
EPS Actual
-$0.20
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2022
Apr 15, 2022
EPS Actual
-$2.20
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
| Q4 FY2023 | $2.09 | $2.09 | $2.09 | 1 |
| Q3 FY2023 | $1.39 | $1.39 | $1.39 | 5 |
| Q2 FY2023 | $1.19 | $1.19 | $1.19 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 17 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 20 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 14 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2023 | Nov 20, 2023 | — | $0.02 | $0.02 | -11.11% |
| — Q3 FY2023 | Aug 21, 2023 | — | $0.03 | $0.03 | -13.04% |
| — Q2 FY2023 | May 22, 2023 | — | $0.11 | $0.12 | +9.01% |
| — Q1 FY2023 | Mar 31, 2023 | — | $0.50 | $0.58 | +16.55% |
| — Q4 FY2022 | Dec 31, 2022 | — | $0.82 | $0.80 | -2.43% |
| — Q4 FY2022 | Nov 14, 2022 | — | $1.04 | $1.00 | -3.85% |
| — Q3 FY2022 | Aug 15, 2022 | — | $1.12 | $1.14 | +1.79% |
| — Q2 FY2022 | Apr 15, 2022 | — | $0.00 | $0.00 | +14.29% |
Q4 FY2023-11.11%
Report Date
Nov 20, 2023
EPS Beat/Miss
—
Price Before
$0.02
Price After
$0.02
Q3 FY2023-13.04%
Report Date
Aug 21, 2023
EPS Beat/Miss
—
Price Before
$0.03
Price After
$0.03
Q2 FY2023+9.01%
Report Date
May 22, 2023
EPS Beat/Miss
—
Price Before
$0.11
Price After
$0.12
Q1 FY2023+16.55%
Report Date
Mar 31, 2023
EPS Beat/Miss
—
Price Before
$0.50
Price After
$0.58
Q4 FY2022-2.43%
Report Date
Dec 31, 2022
EPS Beat/Miss
—
Price Before
$0.82
Price After
$0.80
Q4 FY2022-3.85%
Report Date
Nov 14, 2022
EPS Beat/Miss
—
Price Before
$1.04
Price After
$1.00
Q3 FY2022+1.79%
Report Date
Aug 15, 2022
EPS Beat/Miss
—
Price Before
$1.12
Price After
$1.14
Q2 FY2022+14.29%
Report Date
Apr 15, 2022
EPS Beat/Miss
—
Price Before
$0.00
Price After
$0.00
Beat Rate0 / 8 quarters
Largest Move+16.55% (Q1 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ATRX ends December
Adhera Therapeutics, Inc. (ATRX) most recently reported earnings on November 20, 2023 for Q4 FY2023, posting EPS of $-0.83 (in line with the analyst consensus of —). The next ATRX earnings date is expected around September 1, 2026.
Each quarter, investors track ATRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ATRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ATRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ATRX earnings · 4 questionsAdhera Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. ATRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ATRX historically reports after market close (AMC).
ATRX earnings datewhen is ATRX earningsATRX next earnings datewhen does ATRX report earningsATRX earnings calendar
▸ Source: FMP · Adhera Therapeutics, Inc. SEC filings · US GAAP · Adhera Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026